

## Prof. ATILLA BOZKURT

### Personal Information

**Email:** abozkurt@hacettepe.edu.tr

**Web:** <https://avesis.hacettepe.edu.tr/abozkurt>

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behcet's Disease**  
Goktas M. T., KARACA R. O., KALKISIM S., Cevik L., KILIC L., AKDOĞAN A., BABAOĞLU M. Ö., Bozkurt A., Bertilsson L., YAŞAR Ü.  
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.121, no.4, pp.266-271, 2017 (SCI-Expanded)
- II. **EFFECTS OF GENETIC POLYMORPHISMS OF MULTI DRUG RESISTANCE PROTEIN (MDR1) ON LANSOPRAZOLE METABOLISM IN PEDIATRIC PATIENTS**  
Karaca R. O., Kalkisim S., GÜMÜŞ E., Goktas M. T., YÜCE A., YAŞAR Ü., BOZKURT A., BABAOĞLU M. Ö.  
DRUG METABOLISM AND PHARMACOKINETICS, vol.32, no.1, 2017 (SCI-Expanded)
- III. **Investigation of 1377C/T polymorphism of the Toll-like receptor 3 among patients with chronic hepatitis B**  
Goktas E. F., Bulut C., Goktas M. T., Ozer E. K., Karaca R. O., Kinikli S., Demiroz A. P., Bozkurt A.  
CANADIAN JOURNAL OF MICROBIOLOGY, vol.62, no.7, pp.617-622, 2016 (SCI-Expanded)
- IV. **Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine**  
YAGCIOGLU A. E., Yoca G., AYHAN Y., KARACA R. O., Cevik L., MÜDERRİSOĞLU A., GÖKTAŞ M. A., ENI N., YAZICI M. S., Bozkurt A., et al.  
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.36, no.3, pp.257-261, 2016 (SCI-Expanded)
- V. **mu-Opioid Receptor Gene (OPRM1) Polymorphisms A118G and C17T in Alcohol Dependence: A Turkish Sample**  
GÜREL Ş. C., AYHAN Y., Karaaslan C., Akel H., KARACA R. O., BABAOĞLU M. Ö., YAŞAR Ü., Bozkurt A., Dilbaz N., ULUĞ B. D., et al.  
TURK PSIKIYATRI DERGISI, vol.27, no.2, pp.75-83, 2016 (SSCI)
- VI. **Lower CYP2C9 activity in Turkish patients with Beh double dagger et's disease compared to healthy subjects: a down-regulation due to inflammation?**  
Goktas M. T., Hatta F., KARACA O., KALKISIM S., KILIC L., AKDOĞAN A., BABAOĞLU M. Ö., Bozkurt A., Hellden A., Bertilsson L., et al.  
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.71, no.10, pp.1223-1228, 2015 (SCI-Expanded)
- VII. **Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter**  
Zoto T., KILIÇKAP S., YAŞAR Ü., ÇELİK İ., BOZKURT A., BABAOĞLU M. Ö.  
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.116, no.4, pp.354-360, 2015 (SCI-Expanded)
- VIII. **Association between ADH1C and ALDH2 polymorphisms and alcoholism in a Turkish sample**  
AYHAN Y., GÜREL Ş. C., KARACA O., ZOTO T., HAYRAN M., BABAĞLU M., YAŞAR Ü., Bozkurt A., DILBAZ N., ULUĞ B. D., et al.  
NORDIC JOURNAL OF PSYCHIATRY, vol.69, no.3, pp.233-239, 2015 (SCI-Expanded)
- IX. **Quantitative Characterization of Magnetic Mobility of Nanoparticle in Solution-Based Condition**  
RODOPLU D., BOYACI İ. H., BOZKURT A. G., EKSI H., Zengin A., Tamer U., AYDOĞAN N., ÖZCAN Ş., Tugcu-Demiroz F.  
CURRENT PHARMACEUTICAL DESIGN, vol.21, no.37, pp.5389-5400, 2015 (SCI-Expanded)

- X. **INVESTIGATION OF THE ROLE OF ALLELIC VARIANTS OF MULTIDRUG RESISTANCE GENE (MDR1) ON CLOZAPINE RELATED LEUKOPENIA/AGRANULOCYTOSIS**  
ANIL YAĞCIOĞLU A. E., YOCA G., Karaca R. O., ÇEVİK L., BABAOĞLU M. Ö., AYHAN Y., Eni N., Yazici M. K., BOZKURT A.  
SCHIZOPHRENIA RESEARCH, vol.153, 2014 (SCI-Expanded)
- XI. **Ocular Pharmacokinetics, Safety and Efficacy of Intracameral Moxifloxacin 0.5% Solution in a Rabbit Model**  
Akova Y., ASENSA L., Goktas M., BOZKURT A., YAŞAR Ü., Karabay G., Demiralay E.  
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol.54, no.15, 2013 (SCI-Expanded)
- XII. **Ocular Pharmacokinetics, Safety and Efficacy of Intracameral Moxifloxacin 0.5% Solution in a Rabbit Model**  
ASENSA L., Akova Y. A., GÖKTAŞ M. T., BOZKURT A., YAŞAR Ü., Karabay G., Demiralay E.  
CURRENT EYE RESEARCH, vol.38, no.4, pp.472-479, 2013 (SCI-Expanded)
- XIII. **Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood**  
GÜMÜŞ E., Karaca O., BABAOĞLU M. Ö., BAYSOY G., Balamtekin N., DEMİR H., USLU KIZILKAN N., BOZKURT A., YÜCE A., YAŞAR Ü.  
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.68, no.5, pp.629-636, 2012 (SCI-Expanded)
- XIV. **Effect of Atorvastatin on CYP2C9 Metabolic Activity as Measured by the Formation Rate of Losartan Metabolite in Hypercholesterolaemic Patients**  
YAŞAR Ü., SAİN GÜVEN G., Yardimci Y., KILIÇARSLAN A., BABAOĞLU M. Ö., BOZKURT A.  
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.109, no.2, pp.73-77, 2011 (SCI-Expanded)
- XV. **CYP1A2\*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia**  
Balibey H., Basoglu C., Lundgren S., BABAOĞLU M. Ö., YAŞAR Ü., Herken H., Rane A., BOZKURT A., Cetin M.  
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.21, no.2, pp.93-99, 2011 (SCI-Expanded)
- XVI. **Functional Effects of Endothelial Nitric Oxide Synthase Genetic Polymorphisms on Haemorheological Parameters in Healthy Human Individuals**  
BABAOĞLU M. Ö., Dikmenoglu N., Ileri-Gurel E., Seringec N., Zoto T., YAŞAR Ü., Kayaalp S. O., Bozkurt A.  
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.108, no.3, pp.171-176, 2011 (SCI-Expanded)
- XVII. **Pharmacotherapy resistance in patients undergoing resective epilepsy surgery due to hippocampal sclerosis is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene**  
Yasar U., Babaoglu M. O., Dericioglu N., Bal B., Bozkurt A., Saygi S.  
FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol.22, pp.51, 2008 (SCI-Expanded)
- XVIII. **Clinical and pharmacological variables as a risk factor for nifedipine-induced gingival overgrowth**  
GÜNCÜ G. N., ÇAĞLAYAN F., Dincel A., Bozkurt A., ÖZMEN F., KARABULUT E.  
AUSTRALIAN DENTAL JOURNAL, vol.52, no.4, pp.295-299, 2007 (SCI-Expanded)
- XIX. **Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model**  
Yagci R., Oflu Y., Dincel A., Kaya E., Yagci S., Bayar B., Duman S., Bozkurt A.  
EYE, vol.21, no.7, pp.990-994, 2007 (SCI-Expanded)
- XX. **Lens concentration of ofloxacin and lomefloxacin in an experimental endophthalmitis model**  
Yagci R., Oflu Y., Yagci S., Dincel A., Kaya E., Duman S., Bozkurt A.  
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, vol.68, no.3, pp.184-190, 2007 (SCI-Expanded)
- XXI. **Effect of ocular compression on intraocular penetration of systemic ofloxacin**  
Ugurbas S. H., Can M., Koksall M., Dincel A., Bozkurt A., Bayar B.  
ADVANCES IN THERAPY, vol.24, no.2, pp.394-401, 2007 (SCI-Expanded)
- XXII. **Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients**  
Elkiran T., Harputhioglu H., Yasar U., Babaoglu M. O., Dincel A. K., Altundag K., Ozisik Y., Guler N., Bozkurt A.  
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol.29, no.1, pp.27-32, 2007 (SCI-

Expanded)

- XXIII. **Plasma and gingival crevicular fluid phenytoin concentrations as risk factors for gingival overgrowth**  
Guncu G. N., Caglayan F., Dincel A., Bozkurt A., Saygi S., Karabulut E.  
JOURNAL OF PERIODONTOLOGY, vol.77, no.12, pp.2005-2010, 2006 (SCI-Expanded)
- XXIV. **Inhibitory effect of 5-fluorouracil on cytochrome P4502C9 activity in cancer patients**  
Gunes A., Coskun U., Boruban C., Gunel N., Babaoglu M., Sencan O., Bozkurt A., Rane A., Hassan M., Zengil H., et al.  
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.98, no.2, pp.197-200, 2006 (SCI-Expanded)
- XXV. **Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists**  
Babaoglu M., Bayar B., Aynacioglu A., Kerb R., Abali H., Celik I., Bozkurt A.  
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol.78, no.6, pp.619-626, 2005 (SCI-Expanded)
- XXVI. **Functional impact of CYP2C\*5, CYP2C9\*6, CYP2C9\*8, and CYP2C9\*11 in vivo among black Africans**  
Allabi A., Gala J., Horsmans Y., Babaoglu M., Bozkurt A., Heusterspreute M., Yasar U.  
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol.76, no.2, pp.113-118, 2004 (SCI-Expanded)
- XXVII. **Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report**  
Babaoglu M., Karadag O., Saikawa Y., Altundag K., Elkiran T., Yasar U., Bozkurt A.  
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.60, no.6, pp.455-456, 2004 (SCI-Expanded)
- XXVIII. **CYP2C9 genetic variants and losartan oxidation in a Turkish population**  
Babaoglu M., Yasar U., Sandberg M., Eliasson E., Dahl M., Kayaalp S., Bozkurt A.  
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.60, no.5, pp.337-342, 2004 (SCI-Expanded)
- XXIX. **Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population**  
Babaoglu M., Ocal T., Bayar B., Kayaalp S., Bozkurt A.  
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.59, no.12, pp.875-877, 2004 (SCI-Expanded)
- XXX. **5-fluorouracil-induced coronary spasm: May inhibition of hyperpolarization factors produced by CYP2C enzymes be the cause?**  
Karadag O., Babaoglu M., Altundag K., Elkiran T., Yasar U., Bozkurt A.  
ONCOLOGY, vol.66, no.6, pp.510-511, 2004 (SCI-Expanded)
- XXXI. **Subretinal fluid levels of topical, oral, and combined administered ciprofloxacin in humans**  
Cekic O., Batman C., Yasar U., Basci N. E., Zilelioglu O., Bozkurt A.  
BRITISH JOURNAL OF OPHTHALMOLOGY, vol.84, no.9, pp.1061-1063, 2000 (SCI-Expanded)
- XXXII. **Penetration of topical and oral ofloxacin into the aqueous and vitreous humor of inflamed rabbit eyes**  
Ozturk F., Kurt E., Inan U., Kortunay S., Ilker S., Basci N. E., Bozkurt A.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.204, pp.91-95, 2000 (SCI-Expanded)
- XXXIII. **The protective effect of taurine against gentamicin-induced acute tubular necrosis in rats**  
Erdem A., Gundogan N., Usubutun A., Kilinc K., Erdem S., Kara A., Bozkurt A.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.15, no.8, pp.1175-1182, 2000 (SCI-Expanded)
- XXXIV. **The effects of prolonged acute use and inflammation on the ocular penetration of topical ciprofloxacin**  
Ozturk F., Kurt E., Inan U., Kortunay S., Ilker S., Basci N. E., Bozkurt A.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.204, pp.97-100, 2000 (SCI-Expanded)
- XXXV. **The pharmacokinetics and effects of diltiazem in rabbits**  
Oruc S., Orhan D., Orhan M., Irkec M., Basci N. E., Barun S., Bozkurt A.  
EUROPEAN JOURNAL OF OPHTHALMOLOGY, vol.10, no.1, pp.46-50, 2000 (SCI-Expanded)
- XXXVI. **Optimization of the separation of  $\beta$ -blockers in HPLC**  
Basci N. E., Temizer A., Bozkurt A., Isimer A.  
Journal de Pharmacie de Belgique, vol.53, no.3, pp.156, 1998 (SCI-Expanded)
- XXXVII. **S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.**

- Basci N. E., Brosen K., Bozkurt A., Isimer A., Sayal A., Kayaalp S.  
British Journal of Clinical Pharmacology, vol.38, no.5, pp.463-465, 1994 (SCI-Expanded)
- XXXVIII. **Correlation Between the Metabolic Ratios of Debrisoquine and Metoprolol in Turkish Subjects**  
Basci N. E., Bozkurt A., Isimer A., Kayaalp S.  
Pharmacology & Toxicology, vol.75, no.1, pp.62-64, 1994 (SCI-Expanded)
- XXXIX. **N-ACETYLATION PHENOTYPING WITH SULFADIMIDINE IN A TURKISH POPULATION**  
BOZKURT A., BASCI N. E., KALAN S., TUNCER M., KAYAALP S.  
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.38, no.1, pp.53-56, 1990 (SCI-Expanded)
- XL. **Comparison of colorimetric and high-performance liquid chromatographic determination of sulphamethoxazole and acetylsulphamethoxazole**  
Basci N. E., Bozkurt A., Kayaalp S., Isimer A.  
Journal of Chromatography B: Biomedical Sciences and Applications, vol.527, pp.174-181, 1990 (SCI-Expanded)

### Articles Published in Other Journals

- I. **The effect of CYP2C9 gene polymorphisms on blood pressure lowering response to losartan in patients with essential hypertension**  
Tanrikulu F. P., BABAĞLU M. Ö., ÇAKIR B., BOZKURT A., Guven G. S.  
CUKUROVA MEDICAL JOURNAL, vol.47, no.3, pp.1015-1023, 2022 (ESCI)
- II. **Endothelial nitric oxide synthase G894T, intron 4 VNTR, and T786C polymorphisms in retinopathy of prematurity**  
Tekkeşin F., Yurdakok M., GÜMÜŞ E., BABAĞLU M. Ö., Bozkurt A., Caliskan Kadayifcilar S., Eldem M., KORKMAZ A. C., YİĞİT Ş., Tekinalp G.  
Journal of Neonatal-Perinatal Medicine, vol.15, no.2, pp.249-255, 2022 (Scopus)
- III. **Penetration of topical ciprofloxacin by presoaked medicated soft contact lenses**  
Kalayci D., Basci N. E., Kortunay S., Hasiripi H., Bozkurt A.  
CLAO Journal, vol.25, no.3, pp.182-184, 1999 (Scopus)

### Refereed Congress / Symposium Publications in Proceedings

- I. **Relationship between genetic polymorphisms of multidrug resistance gene MDR1 (ABCB1) and clearance of <sup>99m</sup>Tc-MIBI**  
Kapulu-Akca C., Goktas M., Babaoglu M. O., Altundag K., Yasar U., Celik I., Bozkurt A., Erbas B.  
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Austria, 9 - 13 October 2010, vol.37
- II. **Association of serotonin transporter gene (SLC6A4) polymorphisms with alcohol dependence in a Turkish population**  
KARACA O. R., BABAĞLU M. Ö., YAŞAR Ü., AYHAN Y., GÜREL Ç. S., DILBAZ N., DEMİR B., ULUG B., Bozkurt A.  
9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics (ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.255-256
- III. **Drug transporter gene MDR1 polymorphism C3435T may explain colchicine nonresponsiveness in familial Mediterranean fever**  
Tufan A., Babaoglu M., Akdogan A., Yasar U., Calguneri M., Kalyoncu U., Karadag O., Ertenli A., Bozkurt A., Kiraz S.  
Annual European Congress of Rheumatology (EULAR 2006), Amsterdam, Netherlands, 21 - 24 June 2006, vol.65, pp.100
- IV. **Differential alteration of drug metabolizing enzyme activities in vivo after cyclophosphamide/doxorubicin administration in operable breast cancer patients.**  
Elkiran E., Altundag K., Babaoglu M., Yasar U., Ozisik Y., Guler N., Dincel A., Bozkurt A.  
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May

2005, vol.23

**V. Effects of CYP2C9\*5,\*6,\*8 and \*11 polymorphisms on losartan oxidation among black Africans**

Allabi A, Gala J, Horsmans Y, Babaoglu M, Bozkurt A, Heusterspreute M, Yasar U.

8th World Congress of Clinical Pharmacology and Therapeutics, Brisbane, Australia, 1 - 06 August 2004, vol.31

**VI. Tamoxifen inhibits cytochrome P4502C9 activity: A possible mechanism for tamoxifen-warfarin interaction.**

Boruban M, Babaoglu M, Sencan O, Bozkurt A, Yasar U.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

## **Metrics**

Publication: 49

Citation (WoS): 606

Citation (Scopus): 406

H-Index (WoS): 12

H-Index (Scopus): 10